In contrast, the FISH test did not identify TP53 structural rearrangements in other 124 bone forming tumors and tumor like lesions or in 966 other tumor samples, including 33 prostatic adenocarcinomas. This evidence concerns the gene TP53 and prostate adenocarcinoma.